{"filing":{"accession_number":"0001599298-26-000049","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"smmt-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000049/smmt-20260602.htm"},"events":[{"id":7273,"run_id":6385,"accession_number":"0001599298-26-000049","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses that the Audit Committee and independent directors approved company affiliates to purchase shares under a previously disclosed at-the-market (ATM) offering, with three named executives (Co-CEOs Duggan and Zanganeh, and CFO Soni) indicating likely near-term purchases. ATM offerings are dilutive equity issuances that raise capital by selling shares at prevailing market prices, and executive participation signals confidence but also potential dilution to existing shareholders.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4104,"accession_number":"0001599298-26-000049","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses that the Audit Committee and independent directors approved company affiliates to purchase shares under a previously disclosed at-the-market (ATM) offering, with three named executives (Co-CEOs Duggan and Zanganeh, and CFO Soni) indicating likely near-term purchases. ATM offerings are dilutive equity issuances that raise capital by selling shares at prevailing market prices, and executive participation signals confidence but also potential dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:47:55.603131+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4104,"accession_number":"0001599298-26-000049","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses that the Audit Committee and independent directors approved company affiliates to purchase shares under a previously disclosed at-the-market (ATM) offering, with three named executives (Co-CEOs Duggan and Zanganeh, and CFO Soni) indicating likely near-term purchases. ATM offerings are dilutive equity issuances that raise capital by selling shares at prevailing market prices, and executive participation signals confidence but also potential dilution to existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:47:55.603131+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-03"}]}